BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yuan WX, Gui YX, Na WN, Chao J, Yang X. Circulating microRNA-125b and microRNA-130a expression profiles predict chemoresistance to R-CHOP in diffuse large B-cell lymphoma patients. Oncol Lett 2016;11:423-32. [PMID: 26870228 DOI: 10.3892/ol.2015.3866] [Cited by in Crossref: 39] [Cited by in F6Publishing: 44] [Article Influence: 6.5] [Reference Citation Analysis]
Number Citing Articles
1 Nordmo C, Glehr G, Altenbuchinger M, Spang R, Ziepert M, Horn H, Staiger AM, Ott G, Schmitz N, Held G, Einsele H, Topp M, Rosenwald A, Rauert-Wunderlich H. Identification of a miRNA based model to detect prognostic subgroups in patients with aggressive B-cell lymphoma. Leuk Lymphoma 2021;62:1107-15. [PMID: 33353431 DOI: 10.1080/10428194.2020.1861268] [Reference Citation Analysis]
2 Han Z, Rosen ST, Querfeld C. Targeting microRNA in hematologic malignancies. Curr Opin Oncol 2020;32:535-44. [PMID: 32657797 DOI: 10.1097/CCO.0000000000000657] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Esmeray E, Küçük C. Genetic alterations in B cell lymphoma subtypes as potential biomarkers for noninvasive diagnosis, prognosis, therapy, and disease monitoring. Turk J Biol 2020;44:1-14. [PMID: 32123491 DOI: 10.3906/biy-1908-23] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Strub GM, Perkins JA. MicroRNAs for the pediatric otolaryngologist. International Journal of Pediatric Otorhinolaryngology 2018;112:195-207. [DOI: 10.1016/j.ijporl.2018.06.043] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
5 Craig KKL, Wood GA, Keller SM, Mutsaers AJ, Wood RD. MicroRNA profiling in canine multicentric lymphoma. PLoS One 2019;14:e0226357. [PMID: 31826004 DOI: 10.1371/journal.pone.0226357] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
6 Shi Y, Ding D, Qu R, Tang Y, Hao S. Non-Coding RNAs in Diffuse Large B-Cell Lymphoma. Onco Targets Ther 2020;13:12097-112. [PMID: 33262609 DOI: 10.2147/OTT.S281810] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Carvalho de Oliveira J, Molinari Roberto G, Baroni M, Bezerra Salomão K, Alejandra Pezuk J, Sol Brassesco M. MiRNA Dysregulation in Childhood Hematological Cancer. Int J Mol Sci 2018;19:E2688. [PMID: 30201877 DOI: 10.3390/ijms19092688] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 5.0] [Reference Citation Analysis]
8 Bouvy C, Wannez A, George F, Graux C, Chatelain C, Dogné JM. Circulating MicroRNAs as Biomarkers in Diffuse Large B-cell Lymphoma: A Pilot Prospective Longitudinal Clinical Study. Biomark Cancer 2018;10:1179299X18781095. [PMID: 29977116 DOI: 10.1177/1179299X18781095] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
9 Decruyenaere P, Offner F, Vandesompele J. Circulating RNA biomarkers in diffuse large B-cell lymphoma: a systematic review. Exp Hematol Oncol 2021;10:13. [PMID: 33593440 DOI: 10.1186/s40164-021-00208-3] [Reference Citation Analysis]
10 Kwok GT, Zhao JT, Weiss J, Mugridge N, Brahmbhatt H, MacDiarmid JA, Robinson BG, Sidhu SB. Translational applications of microRNAs in cancer, and therapeutic implications. Noncoding RNA Res 2017;2:143-50. [PMID: 30159433 DOI: 10.1016/j.ncrna.2017.12.002] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 6.0] [Reference Citation Analysis]
11 Bradshaw G, Sutherland HG, Haupt LM, Griffiths LR. Dysregulated MicroRNA Expression Profiles and Potential Cellular, Circulating and Polymorphic Biomarkers in Non-Hodgkin Lymphoma. Genes (Basel) 2016;7:E130. [PMID: 27999330 DOI: 10.3390/genes7120130] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
12 Chebly A, Chouery E, Ropio J, Kourie HR, Beylot-Barry M, Merlio JP, Tomb R, Chevret E. Diagnosis and treatment of lymphomas in the era of epigenetics. Blood Rev 2021;48:100782. [PMID: 33229141 DOI: 10.1016/j.blre.2020.100782] [Reference Citation Analysis]
13 Chen L, Kan Y, Wang X, Ge P, Ding T, Zhai Q, Wang Y, Yu Y, Wang X, Zhao Z, Yang H, Liu X, Li L, Qiu L, Zhang H, Qian Z, Zhao H. Overexpression of microRNA-130a predicts adverse prognosis of primary gastrointestinal diffuse large B-cell lymphoma. Oncol Lett 2020;20:93. [PMID: 32831912 DOI: 10.3892/ol.2020.11954] [Reference Citation Analysis]
14 Hajji N, García-Domínguez DJ, Hontecillas-Prieto L, O'Neill K, de Álava E, Syed N. The bitter side of epigenetics: variability and resistance to chemotherapy. Epigenomics 2021;13:397-403. [PMID: 29932342 DOI: 10.2217/epi-2017-0112] [Reference Citation Analysis]
15 Rapisuwon S, Vietsch EE, Wellstein A. Circulating biomarkers to monitor cancer progression and treatment. Comput Struct Biotechnol J. 2016;14:211-222. [PMID: 27358717 DOI: 10.1016/j.csbj.2016.05.004] [Cited by in Crossref: 83] [Cited by in F6Publishing: 68] [Article Influence: 16.6] [Reference Citation Analysis]
16 Lopez-Santillan M, Larrabeiti-Etxebarria A, Arzuaga-Mendez J, Lopez-Lopez E, Garcia-Orad A. Circulating miRNAs as biomarkers in diffuse large B-cell lymphoma: a systematic review. Oncotarget 2018;9:22850-61. [PMID: 29854319 DOI: 10.18632/oncotarget.25230] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
17 Lv L, Liu Y. Clinical Application of Liquid Biopsy in Non-Hodgkin Lymphoma. Front Oncol 2021;11:658234. [PMID: 33816315 DOI: 10.3389/fonc.2021.658234] [Reference Citation Analysis]
18 Khare D, Goldschmidt N, Bardugo A, Gur-Wahnon D, Ben-Dov IZ, Avni B. Plasma microRNA profiling: Exploring better biomarkers for lymphoma surveillance. PLoS One 2017;12:e0187722. [PMID: 29131834 DOI: 10.1371/journal.pone.0187722] [Cited by in Crossref: 33] [Cited by in F6Publishing: 36] [Article Influence: 8.3] [Reference Citation Analysis]
19 Coiffier B, Sarkozy C. Diffuse large B-cell lymphoma: R-CHOP failure-what to do? Hematology Am Soc Hematol Educ Program 2016;2016:366-78. [PMID: 27913503 DOI: 10.1182/asheducation-2016.1.366] [Cited by in Crossref: 74] [Cited by in F6Publishing: 78] [Article Influence: 18.5] [Reference Citation Analysis]
20 Regazzo G, Marchesi F, Spagnuolo M, Díaz Méndez AB, Masi S, Mengarelli A, Rizzo MG. Diffuse large B-cell lymphoma: Time to focus on circulating blood nucleic acids? Blood Rev 2021;47:100776. [PMID: 33229139 DOI: 10.1016/j.blre.2020.100776] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
21 Fuertes T, Ramiro AR, de Yebenes VG. miRNA-Based Therapies in B Cell Non-Hodgkin Lymphoma. Trends Immunol 2020;41:932-47. [PMID: 32888820 DOI: 10.1016/j.it.2020.08.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
22 Camus V, Jardin F, Tilly H. The value of liquid biopsy in diagnosis and monitoring of diffuse large b-cell lymphoma: recent developments and future potential. Expert Review of Molecular Diagnostics 2017;17:557-66. [DOI: 10.1080/14737159.2017.1319765] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
23 Ting CY, Liew SM, Price A, Gan GG, Bee-Lan Ong D, Tan SY, Bee PC. Clinical significance of aberrant microRNAs expression in predicting disease relapse/refractoriness to treatment in diffuse large B-cell lymphoma: A meta-analysis. Crit Rev Oncol Hematol 2019;144:102818. [PMID: 31733445 DOI: 10.1016/j.critrevonc.2019.102818] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
24 Paszkiewicz-Kozik E, Paziewska A, Kulecka M, Dąbrowska M, Kluska A, Bałabas A, Piątkowska M, Ambrożkiewicz F, Tajer J, Osiadacz W, Romejko-Jarosińska J, Kotarska M, Żeber-Lubecka N, Karczmarski J, Popławska L, Mikula M, Rutkowski P, Walewski J, Ostrowski J. Peripheral Blood Cells from Patients with Hodgkin's and Diffuse Large B Cell Lymphomas May Be a Better Source of Candidate Diagnostic miRNAs Than Circulating miRNAs. Biomed Res Int 2021;2021:3212878. [PMID: 33628777 DOI: 10.1155/2021/3212878] [Reference Citation Analysis]
25 Molinaro C, Martoriati A, Cailliau K. Proteins from the DNA Damage Response: Regulation, Dysfunction, and Anticancer Strategies. Cancers (Basel) 2021;13:3819. [PMID: 34359720 DOI: 10.3390/cancers13153819] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
26 Solé C, Larrea E, Di Pinto G, Tellaetxe M, Lawrie CH. miRNAs in B-cell lymphoma: Molecular mechanisms and biomarker potential. Cancer Letters 2017;405:79-89. [DOI: 10.1016/j.canlet.2017.07.020] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 3.5] [Reference Citation Analysis]
27 Drees EEE, Pegtel DM. Circulating miRNAs as Biomarkers in Aggressive B Cell Lymphomas. Trends Cancer 2020;6:910-23. [PMID: 32660885 DOI: 10.1016/j.trecan.2020.06.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
28 Feng Y, Zhong M, Zeng S, Wang L, Liu P, Xiao X, Liu Y. Exosome-derived miRNAs as predictive biomarkers for diffuse large B-cell lymphoma chemotherapy resistance. Epigenomics 2019;11:35-51. [PMID: 30211623 DOI: 10.2217/epi-2018-0123] [Cited by in Crossref: 41] [Cited by in F6Publishing: 44] [Article Influence: 13.7] [Reference Citation Analysis]
29 Alsaadi M, Khan MY, Dalhat MH, Bahashwan S, Khan MU, Albar A, Almehdar H, Qadri I. Dysregulation of miRNAs in DLBCL: Causative Factor for Pathogenesis, Diagnosis and Prognosis. Diagnostics (Basel) 2021;11:1739. [PMID: 34679437 DOI: 10.3390/diagnostics11101739] [Reference Citation Analysis]
30 Regazzo G, Terrenato I, Spagnuolo M, Carosi M, Cognetti G, Cicchillitti L, Sperati F, Villani V, Carapella C, Piaggio G, Pelosi A, Rizzo MG. A restricted signature of serum miRNAs distinguishes glioblastoma from lower grade gliomas. J Exp Clin Cancer Res 2016;35:124. [PMID: 27476114 DOI: 10.1186/s13046-016-0393-0] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 8.0] [Reference Citation Analysis]
31 Beheshti A, Stevenson K, Vanderburg C, Ravi D, McDonald JT, Christie AL, Shigemori K, Jester H, Weinstock DM, Evens AM. Identification of Circulating Serum Multi-MicroRNA Signatures in Human DLBCL Models. Sci Rep 2019;9:17161. [PMID: 31748664 DOI: 10.1038/s41598-019-52985-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
32 Zhang L, Zhou S, Zhou T, Li X, Tang J. Potential of the tumor‑derived extracellular vesicles carrying the miR‑125b‑5p target TNFAIP3 in reducing the sensitivity of diffuse large B cell lymphoma to rituximab. Int J Oncol 2021;58:31. [PMID: 33887878 DOI: 10.3892/ijo.2021.5211] [Reference Citation Analysis]
33 Marchesi F, Regazzo G, Palombi F, Terrenato I, Sacconi A, Spagnuolo M, Donzelli S, Marino M, Ercolani C, Di Benedetto A, Blandino G, Ciliberto G, Mengarelli A, Rizzo MG. Serum miR-22 as potential non-invasive predictor of poor clinical outcome in newly diagnosed, uniformly treated patients with diffuse large B-cell lymphoma: an explorative pilot study. J Exp Clin Cancer Res 2018;37:95. [PMID: 29716630 DOI: 10.1186/s13046-018-0768-5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 4.7] [Reference Citation Analysis]
34 Di Paolo A, Arrigoni E, Luci G, Cucchiara F, Danesi R, Galimberti S. Precision Medicine in Lymphoma by Innovative Instrumental Platforms. Front Oncol 2019;9:1417. [PMID: 31921674 DOI: 10.3389/fonc.2019.01417] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
35 Zhang HD, Jiang LH, Sun DW, Li J, Ji ZL. The role of miR-130a in cancer. Breast Cancer 2017;24:521-7. [PMID: 28477068 DOI: 10.1007/s12282-017-0776-x] [Cited by in Crossref: 46] [Cited by in F6Publishing: 54] [Article Influence: 11.5] [Reference Citation Analysis]
36 Solé C, Arnaiz E, Lawrie CH. MicroRNAs as Biomarkers of B-cell Lymphoma. Biomark Insights 2018;13:1177271918806840. [PMID: 30349178 DOI: 10.1177/1177271918806840] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 3.7] [Reference Citation Analysis]
37 Jørgensen S, Paulsen IW, Hansen JW, Tholstrup D, Hother C, Sørensen E, Petersen MS, Nielsen KR, Rostgaard K, Larsen MAH, Brown PN, Ralfkiær E, Homburg KM, Hjalgrim H, Erikstrup C, Ullum H, Troelsen J, Grønbæk K, Pedersen OB. The value of circulating microRNAs for early diagnosis of B-cell lymphoma: A case-control study on historical samples. Sci Rep 2020;10:9637. [PMID: 32541886 DOI: 10.1038/s41598-020-66062-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
38 Sun N, Wang C, Sun Y, Ruan Y, Huang Y, Su T, Zhou X, Huang H, Guo W, He M, Yao R, Lin X. Down-regulated miR-148b increases resistance to CHOP in diffuse large B-cell lymphoma cells by rescuing Ezrin. Biomedicine & Pharmacotherapy 2018;106:267-74. [DOI: 10.1016/j.biopha.2018.06.093] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
39 Ayers D, Vandesompele J. Influence of microRNAs and Long Non-Coding RNAs in Cancer Chemoresistance. Genes (Basel) 2017;8:E95. [PMID: 28273813 DOI: 10.3390/genes8030095] [Cited by in Crossref: 69] [Cited by in F6Publishing: 72] [Article Influence: 17.3] [Reference Citation Analysis]
40 Beheshti A, Vanderburg C, McDonald JT, Ramkumar C, Kadungure T, Zhang H, Gartenhaus RB, Evens AM. A Circulating microRNA Signature Predicts Age-Based Development of Lymphoma. PLoS One 2017;12:e0170521. [PMID: 28107482 DOI: 10.1371/journal.pone.0170521] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
41 Cui Q, Vari F, Cristino AS, Salomon C, Rice GE, Sabdia MB, Guanzon D, Palma C, Mathew M, Talaulikar D, Jain S, Han E, Hertzberg MS, Gould C, Crooks P, Thillaiyampalam G, Keane C, Gandhi MK. Circulating cell-free miR-494 and miR-21 are disease response biomarkers associated with interim-positron emission tomography response in patients with diffuse large B-cell lymphoma. Oncotarget 2018;9:34644-57. [PMID: 30410665 DOI: 10.18632/oncotarget.26141] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
42 Zheng B, Xi Z, Liu R, Yin W, Sui Z, Ren B, Miller H, Gong Q, Liu C. The Function of MicroRNAs in B-Cell Development, Lymphoma, and Their Potential in Clinical Practice. Front Immunol 2018;9:936. [PMID: 29760712 DOI: 10.3389/fimmu.2018.00936] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
43 Peng Z, Duan F, Yin J, Feng Y, Yang Z, Shang J. Prognostic values of microRNA-130 family expression in patients with cancer: a meta-analysis and database test. J Transl Med 2019;17:347. [PMID: 31640738 DOI: 10.1186/s12967-019-2093-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
44 Mironova N, Vlassov V. Surveillance of Tumour Development: The Relationship Between Tumour-Associated RNAs and Ribonucleases. Front Pharmacol 2019;10:1019. [PMID: 31572192 DOI: 10.3389/fphar.2019.01019] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]